Immunoglobulins

Immune B cells secrete immunoglobin A antibodies that work on mucosal surfaces in the nose, stomach, and lungs.

Cutaquig was recently approved for the treatment of pediatric patients aged 2 years and older with primary humoral immunodeficiency.

Trial seeks to provide high-level evidence for improving the initial treatment for acute Kawasaki disease.

Factor V Leiden can increase the chance of developing abnormal blood clots, most commonly in the legs or lungs.

Families and providers can use a flexible infusion schedule to meet patient needs, Octapharma says.

IVIG also has an important therapeutic role in cases with multisystem inflammatory syndrome in children (MIS-C), the researchers said.

These results are based on a case report of a patient with LCV associated to sensitive neuropathy for whom systemic treatment was ineffective.

Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.

IVIG has previously been found to be an effective treatment for heart complications caused by Kawasaki disease.

A study finds that intravenous immunoglobulin therapy is a beneficial way to combat parvovirus-induced PRCA in individuals with anemia.

In its most severe form, Guillain-Barre syndrome is a medical emergency.

Cemiplimab is a recombinant human immunoglobulin G4 monoclonal antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.

Tisotumab vedotin, is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

The existence of immunoglobulin G antibodies specifically indicates recent or prior infection and can help identify individuals with an adaptive immune response to SARS-CoV-2.

An intravenous immunoglobulin option along with glucocorticoids could be effective in fighting drug-induced erythroderma for patients with AIDS.

Immune globulin subcutaneous (human), 20% solution (Cuvitru) is approved for primary immunodeficiency in patients 2 years of age and older.

Study results showed that an individual with the blood disorder did not respond to treatment, including intravenous immunoglobulin, following their second dose of the Pfizer vaccination.

Immune Globulins are injections that are used to treat immunodeficiency disorders.

Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.

Octagam 10% is indicated for the treatment of chronic immune thrombocytopenic purpura in adults and dermatomyositis (DM) in adults

A stepwise approach to treatment for multisystem inflammatory syndrome, beginning with initiation of immunomodulatory drugs, was successful in all patients included in the study.

The FDA has approved the first and only intravenous immunoglobulin indicated for use in adults with dermatomyositis.

Home infusion of specialty medications was an outpatient service offered to patients before the pandemic started; however, with COVID-19, home infusion became more important than ever.

Because of its rapid emergence during the COVID-19 pandemic, experts have had to make quick decisions regarding treatment of multisystem inflammatory syndrome with no evidence base and little understanding of its pathophysiological characteristics.

Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.

Xembify (immune globulin subcutaneous human–klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease in patients 2 years of age and older.

Intravenous immunoglobulin is a cornerstone in autoimmune disease treatment.

The use of IVIG in the treatment of recalcitrant pemphigus vulgaris and foliaceus and bullous pemphigoid is supported by 2 clinical trials.

It is important for health care providers to explain compliance to these regimens to patients, both from a clinical and cost perspective.

According to the study authors, 9% of the children receiving the combination therapy did not respond to treatment, compared to 51% of children receiving IVIG alone.